TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23711530
Drug: PCT-guided antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT-guided antibiotic therapy; n = 20
Study: 21841092
Drug: Patient self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-management (PSM) of warfarin therapy
Study: 21841092
Drug: Physician management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician management of warfarin therapy
Study: 18555238
Drug: Microdose GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microdose GnRH agonist (GnRH‐a) flare-up protocol
Study: 15534050
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with proliferative cellular activity, multidrug resistance expression, or receptor status
Study: 11172833
Drug: Cetrorelix acetate
Normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix acetate 1 mg
Study: 11172833
Drug: Cetrorelix acetate
Normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix acetate 5 mg
Study: 11172833
Drug: Cetrorelix acetate
Normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix acetate (1, 3, or 5 mg)
Study: 30486682
Drug: 1 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/day carvacrol
Study: 30486682
Drug: 2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/day carvacrol
Study: 23787501
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (600 mg per day for 14 days)
Study: 18682969
Drug: Timolol-Dorzolamide drops
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol-Dorzolamide drops twice daily (n = 19)
Study: 17052779
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) supplementation 0.4 mg daily
Study: 17052779
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) supplementation 1.0 mg daily
Study: 17052779
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) supplementation 5.0 mg daily
Study: 17052779
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) supplementation (pooled subjects with baseline NT‐proBNP > 40 ng/L)
Study: 11552016
Drug: Long-term immunotherapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term immunotherapy in epsilon4 carriers
Study: 9722293
Drug: CT+G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT+G‐CSF
Study: 26919801
Drug: Colchicine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (mean prescribed dose 2.8 mg within the first 24 hours, cumulative dose 6.9 mg over three days)
Study: 21434379
Drug: Geviskon forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geviskon forte (10 ml, 3 times a day)
Study: 21434379
Drug: Aluminum-magnesium antacid
Normalized name: ALUMINUM/MAGNESIUM HYDROXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-magnesium antacid (1 sachet, 3 times a day)
Study: 12914399
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (iodide 150 microgram + Levothyroxine 75 microgram)
Study: 12914399
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (150 microgram iodide + 75 microgram L-thyroxine)
Study: 12914399
Drug: Levothyroxine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine monotherapy
Study: 12914399
Drug: Iodide or
Normalized name: sodium iodide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodide or combination therapy
Study: 12914399
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups with adequate controls and adjustment of Levothyroxine dosage
Study: 12914399
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Levothyroxine and iodide
Study: 2798990
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg bid)
Study: 9018517
Drug: Glucose (trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (trial G)
Study: 1527319
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate (164 micrograms, twice a day for 7 days)
Study: 28870836
Drug: Clinic-based manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-based manual therapy and individual exercise
Study: 27504562
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antiviral, analgesic, and neurotrophic agents)
Study: 12542199
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg suppository)
Study: 20926006
Drug: Antegrade cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antegrade cardioplegic infusion via the aortic root and additional cardioplegia via vein or free arterial grafts (group B)
Study: 20926006
Drug: Antegrade cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antegrade cardioplegic infusion only via the aortic root (group A)
Study: 16096169
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg estradiol (E(2))
Study: 16096169
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg estradiol (E(2))/3.75 mg nomegestrol acetate (E(2)/NOMAC)
Study: 16096169
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg estradiol (E(2))/3.75 mg nomegestrol acetate (E(2)/NOMAC) vs 1.5 mg estradiol (E(2))
Study: 10968237
Drug: Irbesartan (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (3.3 mg/kg body weight daily)
Study: 6383009
Drug: Protein at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein at a level of 1.5 g/kg desirable weight per day
Study: 29672821
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day, up-titrated to 80 mg after 6 weeks
Study: 29672821
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg/day, up-titrated to 40 mg after 6 weeks
Study: 27109860
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg purified 5‐CGA
Study: 27109860
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg purified 5‐CGA
Study: 27109860
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg purified 5‐CGA (control group)
Study: 27109860
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg purified (‐)‐epicatechin (positive control)
Study: 23273022
Drug: Artemisinin-based combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-based combination therapy (ACT) for uncomplicated malaria
Study: 20959430
Drug: L-arginine hydrochloride
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine hydrochloride (30g infusion)
Study: 16259308
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser acupuncture (0.5J delivered to six to eight acupuncture sites, twice weekly for four weeks then weekly for a further four weeks)
Study: 16259308
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control (inactive laser treatment)
Study: 9762021
Drug: 0.005% calcipotriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% calcipotriol ointment twice daily
Study: 9762021
Drug: 0.3% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% tacrolimus ointment once daily
Study: 9762021
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment once daily
Study: 3432357
Drug: L-tryptophan (L-TRP)
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan (L-TRP) 2 g
Study: 3432357
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose of L-tryptophan (0.04 g)
Study: 31710104
Drug: Galcanezumab 120
Normalized name: Galcanezumab 120 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab 120 mg (with 240 mg loading dose)
Study: 23439365
Drug: IDX184 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 50 mg once daily + pegylated interferon-α2a and ribavirin
Study: 23439365
Drug: IDX184 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 50 mg twice daily + pegylated interferon-α2a and ribavirin
Study: 23439365
Drug: IDX184 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 100 mg once daily + pegylated interferon-α2a and ribavirin
Study: 23439365
Drug: IDX184 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 150 mg once daily + pegylated interferon-α2a and ribavirin
Study: 23439365
Drug: IDX184 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 100 mg twice daily + pegylated interferon-α2a and ribavirin
Study: 23439365
Drug: IDX184 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 200 mg once daily + pegylated interferon-α2a and ribavirin
Study: 22080004
Drug: 0.4 mL
Normalized name: ethanol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mL diluent-injected control
Study: 22080004
Drug: All carbohydrate
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All carbohydrate treatments except glucose and dextrin combination
Study: 22080004
Drug: All carbohydrates
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All carbohydrates except for 25% dextrin treatment
Study: 17228991
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (decaffeinated coffee)
Study: 17228991
Drug: Caffeine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (both treatments)
Study: 8403960
Drug: Methohexital (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (5 mg/mL)
Study: 8403960
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg/mL)
Study: 27045953
Drug: Engage in
Normalized name: Bispecific t-cell engager antibody regn4018
DrugBank: Ubamatamab (DB18875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engage in Education‐London (EiE‐L) intervention
Study: 25193590
Drug: Honey, antibiotic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey, antibiotic, and acetaminophen
Study: 25193590
Drug: Antibiotic and
Normalized name: Triple Antibiotic And Pain Relief
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic and acetaminophen
Study: 22006408
Drug: Tegobuvir 40
Normalized name: Tegobuvir
DrugBank: Tegobuvir (DB11852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegobuvir 40 mg BID + GS-9256 75 mg BID
Study: 22006408
Drug: Tegobuvir 40
Normalized name: Tegobuvir
DrugBank: Tegobuvir (DB11852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegobuvir 40 mg BID + GS-9256 75 mg BID + RBV 1,000-1,200 mg daily
Study: 22006408
Drug: Tegobuvir 40
Normalized name: Tegobuvir
DrugBank: Tegobuvir (DB11852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegobuvir 40 mg BID + GS-9256 75 mg BID + Peg-IFN alpha-2a (180 μg once-weekly) + RBV
Study: 10673254
Drug: Dipyridamole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 0.5 mg/kg infused intravenously for 3 minutes immediately before reperfusion during primary PTCA.
Study: 10673254
Drug: Dipyridamole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 0.5 mg/kg infused intravenously while continuous ECG recordings were obtained.
Study: 6340825
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus immunotherapy with BCG-CWS
Study: 26659931
Drug: Crisaborole topical
Normalized name: crisaborole topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole topical ointment 2% applied twice daily (BID)
Study: 26659931
Drug: Crisaborole topical
Normalized name: crisaborole topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole topical ointment 0.5% or 2% applied once daily (QD)
Study: 26659931
Drug: Crisaborole topical
Normalized name: crisaborole topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole topical ointment 0.5% or 2% applied twice daily (BID)
Study: 22971742
Drug: midazolam +
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam + tramadol (1 mg/kg)
Study: 21514637
Drug: Methotrexate (10-22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (10-22.5 mg/wk)
Study: 21514637
Drug: Azathioprine (1.5-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (1.5-2.5 mg/kg/d)
Study: 18030515
Drug: NSAID therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID therapy followed by methotrexate (MTX) for 3 months after 3 months of NSAID therapy
Study: 18030515
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NSAID and MTX for the entire 6-month period
Study: 17205826
Drug: Compound decoctum
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound decoctum of Tripterygium wilfordii (TW) and liquorice
Study: 17205826
Drug: Tripterygium wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium wilfordii ployglycosidium tablets
Study: 14638353
Drug: Vitamins E
Normalized name: Multiple Vitamins Essentials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins E and C (1000 IU and 1000 mg, respectively) daily for 6 months
Study: 11125871
Drug: Midazolam 12
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 12 mg + Caffeine 250 mg
Study: 11125871
Drug: Midazolam 12
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 12 mg + Caffeine 125 mg
Study: 6139119
Drug: Midazolam 12
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 12 mg
Study: 31092895
Drug: Once-weekly carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly carfilzomib 70 mg/m2 (Kd70 mg/m2)
Study: 31092895
Drug: Twice-weekly carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly carfilzomib 27 mg/m2 (Kd27 mg/m2)
Study: 28259322
Drug: Combination analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination analgesics
Study: 15327411
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 10 mg daily
Study: 17941284
Drug: Fexofenadine hydrochloride,
Normalized name: Fexofenadine Hydrochloride, 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride, 30 mg, twice daily for 2 weeks
Study: 17941284
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 2 weeks
Study: 11562661
Drug: Gelatin-coated Dacron
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin-coated Dacron (GEL-D) grafts (n = 109)
Study: 11562661
Drug: Gelatin-coated Dacron
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin-coated Dacron (GEL-D) grafts
Study: 11562661
Drug: Dacron grafts
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacron grafts (GEL-D and COL-D combined)
Study: 9622279
Drug: 0.5, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5, 1 or 2 mg/day of oral micronized 17beta‐estradiol
Study: 3216364
Drug: Cefamandole (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (1-g intravenous dose)
Study: 3216364
Drug: Cefotaxime (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1-g intravenous dose)
Study: 30479292
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus increased educational information regarding bowel preparation
Study: 30479292
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus increased educational information regarding bowel preparation plus an anti-flatulent medication
Study: 17163273
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day + Amoxicillin 1500 mg/day + Clarithromycin 400 mg/day
Study: 17163273
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day + Amoxicillin 1500 mg/day + Clarithromycin 800 mg/day
Study: 8314475
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interferon (10 million units (MU) given six times a week for two weeks followed by 12 weeks of thrice weekly dosing
Study: 8314475
Drug: Four weeks
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four weeks of 10 MU six times a week followed by eight weeks of thrice weekly dosing
Study: 2963306
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a third generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacin)
Study: 21340523
Drug: MISPTT (minimally
Approvals — FDA: no, EMA: no, PMDA: no
Description: MISPTT (minimally invasive stereotactic puncture and thrombolysis therapy)
Study: 21340523
Drug: Conventional craniotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional craniotomy (CC)
Study: 15337974
Drug: Short 30‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short 30‐G x 0.40 x 6 mm gauge needle
Study: 15337974
Drug: Conventional 25‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 25‐G x 0.50 x 13 mm gauge needle
Study: 23657457
Drug: Breakfasts prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfasts prepared with virgin olive oil (400 μg mL(‐1) of phenolic compounds)
Study: 23657457
Drug: Breakfasts prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfasts prepared with sunflower oils (pure, enriched with dimethylsiloxane, and enriched with phenolic compounds)
Study: 20735877
Drug: Tomato purée
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato purée (70 g)
Study: 19465371
Drug: Manual therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy, exercise, and intermittent cervical traction (MTEXTraction group)
Study: 19465371
Drug: Manual therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy, exercise, and sham intermittent cervical traction (MTEX group)
Study: 15223728
Drug: Losartan 50-100
Normalized name: losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50-100 mg o.d.
Study: 15223728
Drug: Hydrochlorothiazide 12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5-25 mg o.d.
Study: 11966693
Drug: Short-contact dithranol
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-contact dithranol cream followed by clobetasol-17-propionate ointment 5 days per week
Study: 11966693
Drug: Short-contact dithranol
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-contact dithranol cream followed by vehicle of clobetasol-17-propionate ointment
Study: 11966693
Drug: Clobetasol-17-propionate ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol-17-propionate ointment 5 days per week
Study: 7714225
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone 300 mg plus intravenous triazolam
Study: 7714225
Drug: Intravenous triazolam
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous triazolam plus oral placebo
Study: 25532076
Drug: Cariprazine 3-12
Normalized name: cariprazine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 3-12 mg/day
Study: 16790625
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 microg/kg bolus over 10 min, followed by continuous infusion of 0.5 microg.kg(‐1).h(‐1))
Study: 15609652
Drug: Short-duration prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-duration prophylaxis with 4 g of cefmetazole sodium for 2 days
Study: 15609652
Drug: Long-duration prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-duration prophylaxis with 14 g of cefmetazole sodium for 7 days
Study: 11603137
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL 0.5% lignocaine and 50 mg tramadol (group B)
Study: 11603137
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL 0.5% lignocaine and 1 mL normal saline (group A)
Study: 9600792
Drug: Withdrawal period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal period after ibandronate treatment
Study: 8083112
Drug: Sucralfate mouth
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate mouth washing 1 g six times daily during irradiation (n = 20)
Study: 2503553
Drug: Inhaled lysine-aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lysine-aspirin
Study: 2503553
Drug: Inhaled lysine-aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lysine-aspirin with terfenadine premedication
Study: 31958285
Drug: Upper limb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper limb exercise programme (30-min daily for 12 weeks)